Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Eribulin mesylate 1.4 mg/m^2 intravenous Clear all

Conditions: Breast Cancer
Interventions: Sacituzumab govitecan, Eribulin, Capecitabine, Gemcitabine, Vinorelbine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 185
States / cities: Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 144 more

Conditions: Breast Cancer
Interventions: E7389, Physician's Choice; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 32
States / cities: Birmingham, Alabama • Bellflower, California • Gilroy, California + 29 more

Conditions: Breast Neoplasm
Interventions: Eribulin Mesylate, Pembrolizumab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 22
States / cities: Duarte, California • Santa Barbara, California • Denver, Colorado + 16 more

Conditions: Metastatic Breast Cancer
Interventions: Eribulin Mesylate, Capecitabine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 13
States / cities: Anaheim, California • La Verne, California • Poway, California + 10 more

Conditions: Breast Cancer
Interventions: E7389; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 48 more

Conditions: Metastatic Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 55
States / cities: Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more

Conditions: Metastatic Breast Cancer
Interventions: Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more

Conditions: Cancer
Interventions: E7389 + carboplatin AUC 5, E7389+carboplatin AUC 6; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more

Conditions: Breast Cancer
Interventions: Ramucirumab (IMC-1121B), Eribulin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • Gilroy, California • Palm Springs, California + 49 more

Conditions: Metastatic Breast Cancer
Interventions: Anakinra plus Standard of Care; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Neoplasms
Interventions: E7389; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 16
States / cities: Jonesboro, Arkansas • Deer Park, California • La Verne, California + 13 more

Conditions: Soft Tissue Sarcoma
Interventions: Eribulin mesylate 1.4 mg/m^2 intravenous, Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 27 more

Conditions: Breast Cancer
Interventions: Eribulin Mesylate, Ixabepilone; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 50
States / cities: Sedona, Arizona • Hawthorne, California • Los Angeles, California + 39 more

Conditions: Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Interventions: Eribulin mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 36 more

Search by objective public record fields.

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)